U.S. approves Roche-Spark merger

The FTC closes its probe into Roche’s (OTCQX:RHHBY) $4.8B acquisition of Spark Therapeutics (NASDAQ:ONCE).

The agency won’t require any asset sales for the merger to comply with antitrust laws.

The FTC says the investigation “did not indicate that Roche would have the incentive to delay or terminate Spark’s developmental effort for its hemophilia A gene therapy, or that the acquisition would affect Roche’s incentives” for its hemophilia drug.

https://seekingalpha.com/news/3526664-u-s-approves-roche-spark-merger